Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Lei Lei Wu

News Reporter

Bicara’s bispecific antibody treatment on top of Keytruda led to tumor shrinkage in about half of patients with head and neck cancer that has relapsed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ear­ly da­ta show Bicara’s bis­pe­cif­ic helps shrink head and neck can­cers when com­bined with Keytru­da: #AS­CO23

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23